CII
EW icon

CR Intrinsic Investors’s Edwards Lifesciences EW Stock Holding History

CR Intrinsic Investors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,280,000
Closed -$26.5M – 297
2013
Q3 		$26.5M Buy
+2,280,000
New +$26.7M 0.82% 22

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CR Intrinsic Investors's EW Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Edwards Lifesciences (EW) in Q4 2013, closing a stake of 2,280,000 shares — an estimated $26.5M sold.

CR Intrinsic Investors first reported a position in EW in Q3 2013 and held it in 1 quarter. The position peaked at $26.5M in Q3 2013. 407 funds tracked by Wall St. Rank hold EW as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Edwards Lifesciences position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 2,280,000 Edwards Lifesciences shares in Q4 2013, an estimated $26.5M.
  • CR Intrinsic Investors first reported a position in Edwards Lifesciences in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Edwards Lifesciences position peaked at $26.5M in Q3 2013.
  • 407 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.